WAYNE, Pa. & MISGAV, Israel--(BUSINESS WIRE)--Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump(TM) a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on December 13, 2013, the Company was informed by Dr. Sol Barer, Medgenics’ Chairman of the Board of Directors, that he purchased 20,000 shares of common stock on the open market on that day at an average price of $5.3711 per share.
Help employers find you! Check out all the jobs and post your resume.
